| # | Title | Journal | Year | Citations |
|---|
| 1 | Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. | Journal of Clinical Oncology | 1989 | 1,466 |
| 2 | Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. | BMJ: British Medical Journal | 1990 | 679 |
| 3 | Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection | Journal of Clinical Oncology | 2009 | 355 |
| 4 | Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells | Blood | 2008 | 345 |
| 5 | Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment | BMJ: British Medical Journal | 1994 | 307 |
| 6 | Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After High-Dose Therapy With Autologous Hematopoietic Progenitor-Cell Support for Lymphoid Malignancies | Journal of Clinical Oncology | 2000 | 197 |
| 7 | Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma | Journal of Clinical Oncology | 2000 | 192 |
| 8 | Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease | Blood | 1981 | 173 |
| 9 | High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up | Journal of Clinical Oncology | 2000 | 168 |
| 10 | Meta-Analysis to Evaluate the Role of Interferon in Follicular Lymphoma | Journal of Clinical Oncology | 2005 | 165 |
| 11 | Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period | Annals of Oncology | 1995 | 156 |
| 12 | A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results | British Journal of Haematology | 1998 | 153 |
| 13 | The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma | Lung Cancer | 2009 | 134 |
| 14 | Long-term outcome among men with conservatively treated localised prostate cancer | British Journal of Cancer | 2006 | 128 |
| 15 | Emotional support for cancer patients: what do patients really want? | British Journal of Cancer | 1996 | 122 |
| 16 | The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis | Annals of Oncology | 2008 | 122 |
| 17 | Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter | British Journal of Cancer | 1997 | 118 |
| 18 | Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum‐induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer | International Journal of Cancer | 2009 | 115 |
| 19 | Volunteers or victims: patients' views of randomised cancer clinical trials | British Journal of Cancer | 1995 | 109 |
| 20 | Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma | Journal of Clinical Oncology | 2004 | 109 |
| 21 | Randomized placebo-controlled trial of the activity of the morphine glucuronides | Clinical Pharmacology and Therapeutics | 2000 | 108 |
| 22 | Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial | Lancet Oncology, The | 2014 | 106 |
| 23 | Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials | Journal of Clinical Oncology | 2005 | 104 |
| 24 | Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia | Nature | 1987 | 101 |
| 25 | CARBOPLATIN OR CISPLATIN? | Lancet, The | 1988 | 99 |
| 26 | Mutations ofCEBPA in acute myeloid leukemia FAB types M1 and M2 | Genes Chromosomes and Cancer | 2003 | 98 |
| 27 | The changing presentation of germ cell tumours of the testis between 1983 and 2002 | BJU International | 2005 | 97 |
| 28 | Stevens–Johnson syndrome after treatment with rituximab | Annals of Oncology | 2002 | 96 |
| 29 | Predicting etoposide toxicity: relationship to organ function and protein binding. | Journal of Clinical Oncology | 1996 | 93 |
| 30 | Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. | Journal of Clinical Oncology | 1994 | 92 |
| 31 | Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer | British Journal of Cancer | 2008 | 92 |
| 32 | Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab | Oncogene | 2007 | 90 |
| 33 | The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer | Annals of Oncology | 2011 | 85 |
| 34 | An immunohistological and genotypic study of the plasma cell form of Castleman's disease | Histopathology | 1989 | 81 |
| 35 | Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience | Journal of Thoracic and Cardiovascular Surgery | 2015 | 79 |
| 36 | Quality of life: philosophical question or clinical reality? | BMJ: British Medical Journal | 1992 | 74 |
| 37 | Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma | OncoImmunology | 2016 | 74 |
| 38 | Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development | Lancet Oncology, The | 2004 | 73 |
| 39 | The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine | British Journal of Clinical Pharmacology | 2000 | 72 |
| 40 | A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer | Annals of Oncology | 2014 | 71 |
| 41 | Transplacental effects of maternal cancer chemotherapy. Case report | BJOG: an International Journal of Obstetrics and Gynaecology | 1989 | 67 |
| 42 | The management of follicular lymphoma | Annals of Oncology | 1991 | 65 |
| 43 | Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies | Blood | 2008 | 65 |
| 44 | A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia | British Journal of Cancer | 1993 | 62 |
| 45 | Loss of CD30 expression in metastatic embryonal carcinoma: the effects of chemotherapy? | Histopathology | 2001 | 60 |
| 46 | Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity Allografting | Journal of Clinical Oncology | 2003 | 60 |
| 47 | Primary Follicular Lymphoma of the Testis and Epididymis in Adults | American Journal of Surgical Pathology | 2007 | 60 |
| 48 | Morphine 6‐glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret | British Journal of Pharmacology | 1992 | 59 |
| 49 | Reversible posterior leukoencephalopathy syndrome following CHOP chemotherapy for diffuse large B-cell lymphoma | Annals of Oncology | 2001 | 56 |
| 50 | Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin’s Lymphoma | Journal of Clinical Oncology | 2003 | 56 |
